Cellular effects of CPT-11 on colon carcinoma cells: Dependence on p53 and hMLH1 status

International Journal of Cancer

Volumn 101, Issue 1, 2002, Pages 23-31

  Magrini, Roberta ^a   Bhonde, Mandar R ^a   Hanski, Marie Luise ^a   Notter, Michael ^a   Scherbl, Hans ^a   Richard Boland, C ^b   Zeitz, Martin ^a   Hanski, Christoph ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Apoptosis; Cell cycle arrest; Chemotherapy; Colon carcinoma; Irinotecan; p53

Indexed keywords

CELL DNA; DNA FRAGMENT; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE; PROTEIN MLH1; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA DEGRADATION; ENZYME PHOSPHORYLATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL;

APOPTOSIS; BLOTTING, WESTERN; CAFFEINE; CAMPTOTHECIN; CARRIER PROTEINS; CDC2 PROTEIN KINASE; CELL CYCLE; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE DELETION; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036722801     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10565     Document Type: Article

References (43)

1. Irinotecan in the treatment of colorectal cancer: Clinical overview
2. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
3. Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy
4. Efficacy and toxicity of irinotecan in patients with colorectal cancer
5. DNA topoisomerase I poisons
6. CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinants
7. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human nonsmall cell lung cancer: Characterization and mechanism of resistance
8. Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: Relation with their sensitivity to CTP-11
9. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: A potential surrogate end point to assess treatment effectiveness
10. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line
11. p53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative
12. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors
13. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells
14. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status
15. Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells
16. Response of metastatic colorectal cancers to treatment with CPT11 (irinotecan): Implications of the mismatched base repair system
17. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells
18. The "comparative growth assay": Examining the interplay of anti-cancer agents with cells carrying single gene alterations
19. Resistance to topoisomerase poisons due to loss of DNA mismatch repair
20. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines
21. Close correlation between mutations of E2F4 and hMSH3 genes in colorectal cancers with microsatellite instability
22. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation
23. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
24. Determinants of CPT-11 and SN-38 activities in human lung cancer cells
25. Ectopic pl6(ink4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-smallcell-lung-cancer cells
26. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity
27. p53 affects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells
28. DNA damage is able to induce senescence in tumor cells in vitro and in vivo
29. Mechanisms of G2 arrest in response to overexpression of p53
30. p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint
31. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint
32. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N′-nitro-N-nitrosoguanidine
33. Apoptosis in small intestinal epithelial from p53-null mice: Evidence for a delayed, p53-independent G2/M-associated cell death after gamma-irradiation
34. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival
35. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
36. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage
37. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines
38. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage
39. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts
40. Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells
41. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2
42. Repair of double-strand breaks by homologous recombination in mismatch repair-defective mammalian cells
43. Cell-cycle arrestversus cell death in cancer therapy